Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian M Thompson

Showing results (291-300 of 484) with videos related to

Pageof 49
Sort By:
The Journal of Urology|October 20, 2009
Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detectionStephen J Eyre, Donna P Ankerst, John T Wei, et al.
Biometrical Journal. Biometrische Zeitschrift|November 19, 2011
Updating risk prediction tools: a case study in prostate cancerDonna P Ankerst, Tim Koniarski, Yuanyuan Liang, et al.
The Journal of Urology|April 20, 2013
SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-GuérinEila C Skinner, Bryan Goldman, Wael A Sakr, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 28, 2025
Emerging Strategies for Drug-Based Cancer Risk ReductionMaria Daca-Álvarez, Angelo Brunori, Alessio Carbone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2010
Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancerTanya B Dorff, Bryan Goldman, Jacek K Pinski, et al.
World Journal of Urology|November 17, 2010
Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: a tale of two methodsIan M Thompson, Shady Salem, Sam S Chang, et al.
Scientific Reports|March 1, 2016
Roles of Distal and Genic Methylation in the Development of Prostate Tumorigenesis Revealed by Genome-wide DNA Methylation AnalysisYao Wang, Rohit Ramakant Jadhav, Joseph Liu, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 8, 2010
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressivenessLori J Sokoll, Martin G Sanda, Ziding Feng, et al.
JAMA Oncology|April 1, 2016
A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial BiopsyJames McKiernan, Michael J Donovan, Vince O'Neill, et al.
Journal of the National Cancer Institute|September 14, 2012
Health-related quality-of-life findings for the prostate cancer prevention trialCarol M Moinpour, Amy K Darke, Gary W Donaldson, et al.
Pageof 49

Showing results (291-300 of 484) with videos related to

Sort By:
Pageof 49
The Journal of Urology|October 20, 2009
Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detectionStephen J Eyre, Donna P Ankerst, John T Wei, et al.
Biometrical Journal. Biometrische Zeitschrift|November 19, 2011
Updating risk prediction tools: a case study in prostate cancerDonna P Ankerst, Tim Koniarski, Yuanyuan Liang, et al.
The Journal of Urology|April 20, 2013
SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-GuérinEila C Skinner, Bryan Goldman, Wael A Sakr, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 28, 2025
Emerging Strategies for Drug-Based Cancer Risk ReductionMaria Daca-Álvarez, Angelo Brunori, Alessio Carbone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2010
Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancerTanya B Dorff, Bryan Goldman, Jacek K Pinski, et al.
World Journal of Urology|November 17, 2010
Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: a tale of two methodsIan M Thompson, Shady Salem, Sam S Chang, et al.
Scientific Reports|March 1, 2016
Roles of Distal and Genic Methylation in the Development of Prostate Tumorigenesis Revealed by Genome-wide DNA Methylation AnalysisYao Wang, Rohit Ramakant Jadhav, Joseph Liu, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 8, 2010
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressivenessLori J Sokoll, Martin G Sanda, Ziding Feng, et al.
JAMA Oncology|April 1, 2016
A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial BiopsyJames McKiernan, Michael J Donovan, Vince O'Neill, et al.
Journal of the National Cancer Institute|September 14, 2012
Health-related quality-of-life findings for the prostate cancer prevention trialCarol M Moinpour, Amy K Darke, Gary W Donaldson, et al.
Pageof 49